Santiago De Compostela

• LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib in RET fusion-Positive NSCLC Recruiting
  2023-506784-33-00 5 2021-01-19 RET fusion-Positive NSCLC
• A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Nipocalimab in Adults with Moderate to Severe Systemic Lupus E … Recruiting
  2025-523552-31-00 5 2026-05-07 Systemic Lupus Erythematosus
• A study to compare Venetoclax Azacitidine and Quizartinib Vs Venetoclax and Azacitidine in newly diagnosed acute myeloid leukemia patient´s … Recruiting
  2025-522979-29-00 5 2026-04-30 Acute myeloid leukemia
• A Phase 3 Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Zasocitinib in Pediatric Participants Aged 4 to Less … Recruiting
  2025-522567-15-00 5 2026-04-28 Plaque Psoriasis
• A research study comparing how well different doses of the medicine NNC0662-0419 lower blood sugar in people with type 2 diabetes Recruiting
  2025-523260-20-00 4 2026-04-28 type 2 diabetes
• Phase 2 Study of iadademstat for the treatment of patients with essential thrombocythemia resistant/intolerant to hydroxyurea. Recruiting
  2025-523864-19-00 4 2026-04-23 Essential Thrombocythemia
• AMAZE 5: A research study investigating how well the medicine NNC0487-0111 helps people with excess body weight and knee osteoarthritis lose … Recruiting
  2024-520444-42-00 5 2026-04-15 Overweight or obesity, and knee osteoarthritis
• AMAZE 6: A research study investigating how well the medicine NNC0487-0111 helps people with excess body weight and knee osteoarthritis lose … Recruiting
  2024-520445-23-00 5 2026-04-15 Overweight or obesity, and knee osteoarthritis
• A Phase 3 Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children with Short Statur … Recruiting
  2025-523079-44-00 5 2026-04-15 Turner Syndrome (TS)
• An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's Disease Recruiting
  2025-521036-11-00 5 2026-03-23 Immune system disseases
• A study to learn about the effectiveness and safety of different doses of JNJ-88545223 in people with active psoriatic arthritis Recruiting
  2025-523141-10-00 4 2026-03-20 Active Psoriatic Arthritis
• A Study to Learn About the Study Medicine Called Ritlecitinib in People With Hives Without a Known Cause Recruiting
  2025-522642-44-00 4 2026-03-18 CHRONIC SPONTANEOUS URTICARIA
• Evaluation of efficacy and safety of early in hospital initiation of inclisiran treatment in patients with acute coronary syndromes Recruiting
  2025-521670-34-00 5 2026-03-04 Acute coronary syndrome (ST-elevation myocardial infarction [STEMI] or
• An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis Recruiting
  2025-521035-37-00 5 2026-03-02 Immune system diseases
• A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratum … Recruiting
  2025-520897-21-00 10 2026-02-25 Multiple Myeloma
• A trial to learn how safe Dato-DXd is and how well it works in people with NSCLC that has advanced after receiving osimertinib Recruiting
  2024-511362-37-00 5 2026-02-18 Non squamous non-small cell lung cancer (NSCLC)
• Patient-Centered Study of T-DXd in Metastatic HER2-Positive Breast Cancer with Real-Life Side Effect Management Recruiting
  2025-521805-41-00 5 2026-02-18 Patients with HER2-positive, locally advanced or metastatic breast can
• Lp(a) lowering study of pelacarsen (TQJ230) with background inclisiran in participants with elevated Lp(a) and established ASCVD Recruiting
  2024-516356-18-00 5 2026-02-17 Atherosclerotic cardiovascular disease (ASCVD)
• A clinical trial to learn about the effects of DZR123 and JSB462 given together in men with advanced prostate cancer that has stopped respon … Recruiting
  2025-521880-10-00 9 2026-02-16 Metastatic castrate resistant prostate cancer (mCRPC)
• A Study to Assess Adverse Events, Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Ad … Recruiting
  2025-521124-29-00 10 2026-02-13 Non-Small Cell Lung Cancer
• A Global Phase III Study of Puxitatug Samrotecan (AZD8205) Monotherapy Compared with Physician’s Choice of Chemotherapy for B7-H4-Selected E … Recruiting
  2024-518777-34-00 5 2026-02-11 B7-H4-Selected Advanced/Metastatic Endometrial Cancer.
• ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting
  2025-522960-34-00 5 2026-02-09 Established cardiovascular disease
• A study to compare different doses of RO7268489 with a placebo (as add-on therapy to ocrelizumab) in people with multiple sclerosis that has … Recruiting
  2025-521636-10-00 4 2026-02-04 Progressive Forms of Multiple Sclerosis (PMS)
• A Study to Assess the Long-Term Efficacy and Safety of Afimkibart (RO7790121) in Patients with Atopic Dermatitis who participated in previou … Recruiting
  2025-520771-59-00 4 2026-02-03 Atopic Dermatitis

Showing 121–144 of 662 trials